C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

Completed · Phase 2

Conditions studied: Antibody Mediated Rejection of Kidney Transplant

In brief

This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.

Key facts

Study ID

NCT02936479

Run by

NYU Langone Health

People needed

1

Starts

2016-10-01

Expected to finish

2018-10-30

Last updated by the study team

2019-07-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant with acute antibody mediated rejection refractory to standard therapy

You may not qualify if…

• Patients with known intolerance of or anaphylaxis to Berinert

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.